The Pharma Data

NOVEMBER 15, 2020

We have fully equipped labs for all stages of drug discovery, including medicinal chemistry, cellular pharmacology, and molecular pharmacology, as well as an “ in silico ” lab for our computational chemistry, bioinformatics, and data mining activities. . OSS, Netherlands , Nov.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

Drug Target Review

APRIL 5, 2024

For example, a CDMO with deep sequencing knowledge and a proprietary cell line will achieve significantly better performance than CDMOs that license third-party technologies. Skilled CDMOs can also locate or create favourable genomic microenvironments where transcription factors are efficiently recruited, further boosting protein production.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

Drug Target Review

APRIL 11, 2025

His leadership has driven international commercial success in areas including image analysis, data management, bioinformatics, advanced clinical trial data analysis leveraging machine learning and federated learning.

Clinical Development 52

Clinical Development Drugs Pharmaceuticals Clinical Trials 52

DrugBank

MARCH 15, 2023

The moment you decide which DrugBank license or products best suit your needs isn’t the final step in our relationship, it is just the beginning. Depending on your unique needs, license*, and project goals, you might interact with all of them firsthand, or you might be off and running with just a little help from one team.

Licensing 52

Licensing Licensing International Bioinformatics 52

The Pharma Data

DECEMBER 27, 2020

United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership.

FDA 52

FDA Bioinformatics Disease Production 52

The Pharma Data

JULY 27, 2021

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.

Production 52

Production Clinical Trials Government Disease 52